Angiotensin-II Binding May Explain Clotting Impairment
The hormone binds to a clotting protein in mice, offering new insight for patients with high blood pressure.
Updated on Oct. 26, 2026 in Stroke
Live Poll
Do you believe new research into biological mechanisms will improve treatment for severe medical conditions?
Researchers have discovered that the hormone Angiotensin-II can directly bind to a protein called antithrombin to interfere with blood clotting. This interaction may help explain why high blood pressure is linked to both clot formation and bleeding complications.
Why it matters
Understanding this molecular interaction offers new insights into the paradox where the same hormone promotes both thrombosis and bleeding. The findings could eventually lead to new therapeutic strategies for managing hemorrhage risks in patients with hypertensive conditions.
This preclinical study utilized site-directed mutagenesis and mouse models to demonstrate that Angiotensin-II binds to antithrombin with a dissociation constant of 14.1 micromolar. Researchers have not yet confirmed the clinical impact of this pathway in humans.
The players
Nature Communications
An open-access, peer-reviewed scientific journal that publishes research in the biological, health, physical, chemical, and earth sciences.
The details
Angiotensin-II binds directly to antithrombin, triggering a heparin-like change that suppresses thrombin activity and disrupts normal coagulation. By mapping this interaction to the R184 residue on the antithrombin protein, scientists demonstrated how the hormone creates a bleeding risk. In hypertensive mouse models, neutralizing this hormone successfully shortened bleeding times and restored coagulation capacity.
Timeline
October 26, 2026: The study findings were published in Nature Communications.
Health Landscape
This discovery marks a departure from traditional views of blood pressure-related bleeding by identifying a direct molecular mechanism of coagulation impairment. It provides a specific target for future drug development in the field of hypertensive intracerebral hemorrhage research.
While this research is currently limited to preclinical models, it highlights the importance of managing hypertension to reduce vascular complications. Patients with concerns about bleeding or clotting risks should discuss their blood pressure management plan with their physician.
The takeaway
The direct binding of Angiotensin-II to antithrombin is a newly identified factor that may destabilize the body's clotting system. Maintaining healthy blood pressure remains a critical preventive step, and patients should continue to monitor cardiovascular markers alongside their clinical team.
Further reading
Learn more about the latest research on Stroke.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you believe new research into biological mechanisms will improve treatment for severe medical conditions?
